Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
Regensburg Center for Interventional Immunology, Regensburg, Germany.
Nat Commun. 2021 May 21;12(1):3006. doi: 10.1038/s41467-021-23334-2.
Coronavirus disease 2019 (COVID-19) can lead to pneumonia and hyperinflammation. Here we show a sensitive method to measure polyclonal T cell activation by downstream effects on responder cells like basophils, plasmacytoid dendritic cells, monocytes and neutrophils in whole blood. We report a clear T cell hyporeactivity in hospitalized COVID-19 patients that is pronounced in ventilated patients, associated with prolonged virus persistence and reversible with clinical recovery. COVID-19-induced T cell hyporeactivity is T cell extrinsic and caused by plasma components, independent of occasional immunosuppressive medication of the patients. Monocytes respond stronger in males than females and IL-2 partially restores T cell activation. Downstream markers of T cell hyporeactivity are also visible in fresh blood samples of ventilated patients. Based on our data we developed a score to predict fatal outcomes and identify patients that may benefit from strategies to overcome T cell hyporeactivity.
新型冠状病毒病 2019(COVID-19)可导致肺炎和过度炎症。在这里,我们展示了一种灵敏的方法,通过对全血中的反应细胞(如嗜碱性粒细胞、浆细胞样树突状细胞、单核细胞和中性粒细胞)的下游效应来测量多克隆 T 细胞的活化。我们报告了住院 COVID-19 患者中明显的 T 细胞反应低下,在需要通气的患者中更为明显,与病毒持续存在时间延长有关,并且随着临床康复而可逆。COVID-19 诱导的 T 细胞反应低下是 T 细胞外在的,由血浆成分引起,与患者偶尔接受免疫抑制药物无关。男性的单核细胞反应强于女性,IL-2 部分恢复 T 细胞活化。通气患者的新鲜血液样本中也可见 T 细胞反应低下的下游标志物。基于我们的数据,我们开发了一种评分来预测致命结局,并识别可能受益于克服 T 细胞反应低下的策略的患者。